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We report the first case of a patient with severe acute respiratory failure who underwent fibro-
bronchoscopy with oxygen administration provided by high-flow nasal cannula.
We present the case of a patient with severe myasthenia gravis who was admitted to the
Department of Intensive Care Medicine of our hospital with severe acute respiratory failure.
The muscle weakness inherent to the patient’s underlying condition made expectoration of
respiratory secretions difficult and led to the development of bilateral atelectasis. Non-invasive
mechanical ventilation sessions were established, but there was no significant clinical improve-
ment; hence, oxygen administration by humidified high-flow nasal cannula (Optiflow, Fisher &
Paykel, New Zealand) was decided. The patient experienced a subjective improvement,
a decrease in respiratory rate, and an improvement in oxygenation, which, following appro-
priate premedication, allowed diagnosticetherapeutic bronchoscopy to be performed at
bedside,without requiring endotracheal intubation ormechanical ventilation for the procedure.
The improvement experienced by the patient with high-flow nasal cannula, following appro-
priate premedication, allowed diagnosticetherapeutic bronchoscopy to be performed.
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Myasthenia gravis (MG) is an autoimmune disease charac-
terized by fluctuating weakness of the skeletal muscula-
ture. The condition progresses to severe acute respiratory
failure requiring Intensive Care Unit (ICU) admission and
mechanical ventilation in 15e27% of cases.1,2 Patients with
MG can present with alveolar hypoventilation and difficulty
for expectoration, with subsequent accumulation of
secretions and development of pulmonary atelectasis.1
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for diagnosing respiratory diseases (Fig. 1). There are
several indications for this examination in critical patients,
ranging from simple diagnosis of respiratory tract or
pulmonary parenchyma disease to therapeutic measures,3
such as endotracheal tube placement or aspiration of
secretions. Nonetheless, the technique is associated with
a series of risks, such as hemorrhage, cardiac arrhythmia,
bronchospasm, pneumothorax, pneumomediastinum, tran-
sient hypoxemia, and respiratory infection.3 When a tech-
nique such as FBS is carried out in hypoxemic patients
breathing spontaneously, the hypoxemia can be exacer-
bated, making the technique intolerable and requiring
endotracheal intubation (ETI) and mechanical ventilation.
For this reason, the use of FBS is sometimes limited.
Recently, a method was described in which high-flow
oxygen is delivered through a nasal cannula with an active
humidification system that optimizes oxygen administration
in adult patients with acute respiratory failure (ARF).4
Although there are no published reports of its use in FBS, it is
reasonable to believe that the system could be useful in such
procedures. The high-flow nasal cannula (HFNC) has been
tested in healthy volunteers,5 in stable chronic obstructive
pulmonary disease (COPD) patients,6 and in patients who
have undergone abdominal surgery.7 We report the first case
of a patient with severe ARF who underwent FBSwith oxygen
administration provided by HFNC.
Clinical case report
A 32-year-old woman, smoker, with a history of bronchial
asthma showing no decompensations, and hypothyroidism
secondary to thyroidectomy at the age of 15 for Gravese
Basedow disease. In May 2007, the patient experienced flu-
like symptoms with acute respiratory failure requiring ETI.
She was diagnosed with type V MG (positive antibodies to
acetylcholine receptors [AChR]) and underwent a percuta-
neous tracheostomy for prolonged mechanical ventilation.
The patient was scheduled for admission to our center
for elective surgical resection of the thymus, which was
carried out with no intraoperative incidents. Following
surgery she received 2 g iv of metamizole (no knownFigure 1 Chest X-ray before the first fibrobronchoscopy
procedure.allergies) and during the postoperative, she presented with
generalized skin pruritus, tachypnea, and labored
breathing with progressive hypoxia. Treatment was started
with bronchodilators, corticoids, and pyridostigmine and
she was admitted to the ICU for severe ARF.
At the time of ICU admittance, the patient was
conscious, oriented, and afebrile. She was hemodynami-
cally stable with blood pressure at 125/85 mmHg and heart
rate at 80 bpm in sinus rhythm. She showed resting
tachypnea of 25 respirations per minute (rpm), signs
consistent with bronchospasm on auscultation and severe
hypoxemia with a PaO2/FIO2 ratio of 62 mmHg. The
analytical parameters were within normal limits with the
exception of leukocyte count at 15,600 109 cells/L (84%
neutrophils). Treatment with beta-mimetic drugs, corti-
coids, and pyridostigmine was maintained, and antibiotic
treatment was started, based on suspected exacerbation of
the neuromuscular disease secondary to an underlying
infectious process. Because of the severity and progression
of respiratory failure, she was given additional immuno-
suppressive therapy (FK-506) and immunoglobulins (28 g)
for 5 days.
Initially, the patient was administered oxygen therapy
with a Venturi mask (VM) and flow 12e15 Lpm of oxygen.
Physiotherapy was started, N-acetyl-cysteine (Mucofluid,
MESNA) was given to facilitate expectoration of bronchial
secretions and non-invasive mechanical ventilation (NIV)
sessions were initiated. Nevertheless NIV was bad toler-
ated and oxygen administration by humidified HFNC
(Optiflow, Fisher & Paykel, New Zealand) was estab-
lished at 40e50 Lpm and FIO2 1. HFNC use resulted in
a subjective improvement in the sensation of dyspnea
perceived by the patient, a decrease in the respiratory
rate (28 rpm with VM vs. 19 rpm with HFNC) and
improved oxygenation after only 30 min of use (PaO2/FIO2
with VM: 128 mmHg vs. PaO2/FIO2 with HFNC: 235 mmHg).
After 72 h of hospitalization, respiratory failure per-
sisted despite all the measures and treatments applied.
A decision was made to perform FBS within the ICU; the
patient was conscious and breathing spontaneously (HFNC
at 40 Lpm and FIO2 at 1). Before the procedure, she was
given 1 mg intravenous (IV) atropine, and mild sedatione
analgesia with 0.15 mg IV fentanyl, 140 mg IV propofol,
15 mg IV midazolam, and remifentanil IV perfusion at 6 mg/
kg/min. The procedure lasted approximately 15 min and
the patient was hemodynamically stable and showed SpO2
90% throughout. Arterial blood gas values were pH 7.33,
pO2 121 mmHg, and pCO2 68.5 mmHg before FBS, and pH
7.54, pO2 106 mmHg, and pCO2 39 mmHg following FBS.
Fibrobronchoscopy disclosed the presence of abundant
thick, purulent respiratory secretions obstructing the mid-
dleelower right and lower left bronchi. Bronchoalveolar
lavage was performed and samples were taken for micro-
biological study. No microorganisms were isolated.
Following FBS there was a transient clinical improvement
but a left basal atelectasis persisted at the chest X-ray
(Fig. 2). Subsequently, the patient again showed labored
breathing, muscle fatigue, and alveolar hypoventilation that
ultimately required ETI and NIV. She was administered
immunoglobulins, the pyridostigmine dose was reduced
because of abundant bronchorrhea, nebulized DNAse (Pul-
mocyne, rhDNA, Genetech) was initiated to facilitate
Figure 2 Chest X-ray after the first FBS.
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performed to treat recurrent atelectasis in the left lungbase.
She showed gradual clinical improvement, was extubated,
and at 13 days of hospitalization, was discharged (Fig. 3).
Discussion
Myasthenia gravis is an autoimmune disease associated with
an AChR deficit at the neuromuscular junction, character-
izedbymuscleweakness and fatigue that are exacerbated by
activity and partially improves with rest. It mainly affects
women 20e40 years of age. The disease is classified into
different grades (IeV) according to the extension of the
manifestations and is often associated with other autoim-
mune conditions, particularly those affecting the thyroids.
The diagnosis of MG is based on detection of anti-AChR
antibodies in plasma, electrophysiologic evidence of alter-
ations in neuromuscular transmission with repeated stimuli,
and/or improvements in muscle weakness with administra-
tion of anti-cholinesterase agents (edrophonium test). The
disease has an unpredictable clinical course, generally
marked by periods of exacerbation and remission.8
Patients with MG are admitted to the ICU when they
present, or are at risk of presenting with a myasthenic crisis,Figure 3 Chest X-ray at intensive care unit discharge.which is defined as a severe aggravation of muscle weakness
with respiratory failure requiring ETI or postponement of
extubation beyond 24 h after surgery.2,8 In addition to
treatment with anti-cholinesterase drugs, immunosup-
pressors, immunoglobulins, and plasmapheresis, mechanical
ventilation remains an essential support measure in the
severe respiratory failure these patients develop, secondary
to alveolar hypoventilation and accumulation of secretions.9
Pulmonary atelectasis is a common complication, and when
it persists, can lead to worsening of the preexisting hypox-
emia and the development of respiratory infection.1
Therefore, early use of an examination such as FBS
may be indicated. Nonetheless, there is an (undocumented)
impression among intensive care specialists that the use of
certain techniques, such as FBS, can be limited in
spontaneously breathing patients with severe hypoxemia
because of the risk that ETI and mechanical ventilation may
be needed.
The high-flow oxygen treatment has been previously
used for neonates.10 Now, it is available for adult patients.
It consists of a device that combines a nasal cannula with an
active humidification system to allow administration of
highly humidified, high-flow oxygen (Optiflow, Fisher &
Paykel, New Zealand).4 The high-flow delivery decreases
dilution of the inhaled oxygen, and the considerable
humidification may facilitate elimination of secretions. In
a recent study conducted in our center comparing HFNC
with the VM, we found that in patients given oxygen via
HFNC, PaO2/FIO2 improved and respiratory rate decreased
without changes in the pH or PaCO2. In addition, a subjec-
tive assessment of the device was performed and patients
reported milder oral mucosa dryness and greater comfort as
compared to the VM.4
The improvement in oxygenation seen in patients using
HFNC can be explained by several factors. First, nasal
cannulas made of a well-tolerated material are used
instead of conventional nasalebuccal masks.12 Second,
administration of high-flow oxygen may decrease dilution
with room air by more completely satisfying the patient’s
inhalational flow demand.5e7,11 Third, high-flow adminis-
tration may decrease the dead space (wash-out effect).6 In
addition, a possible flow-dependent effect with continuous
positive airway pressure (CPAP) has been documented in
healthy volunteers5 and in patients with COPD.6 Lastly, the
use of high humidity levels may prevent changes in the
pseudostratified ciliated epithelium of the airways, main-
tain mucociliary system activity, facilitate elimination of
secretions, reduce atelectasis formation, and thereby,
indirectly improve oxygenation. In addition, the respiratory
rate is lower in patients receiving oxygen through HFNC,4,6
a fact that may result in better tolerance to exercise.
We believe that HFNC is likely to have an increasingly
important role in facilitating the practice of certain inva-
sive procedures in hypoxemic patients. The value of this
technique was illustrated in the patient reported herein,
who remained stable and showed acceptable oxygenation
during the entire endoscopy procedure. This excellent
tolerance can be explained, at least in part, by the opti-
mized oxygen supply she received, supported by correct
premedication. Administration of drugs such as atropine,
which helps to decrease bronchial secretions and prevents
bradycardia and bronchoconstriction, as well as mild
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collaboration, and produces an amnesic effect, make FBS
more comfortable for the patient. Nonetheless, the tech-
nique should always be performed by an expert fibro-
bronchoscopy operator in these cases.
However this case has one limitation. The duration of the
respiratory failure before FBS could decrease its effective-
ness, indeed in the case of this patient FBS was perfectly
tolerated but she finally needed ETI due to excessive fatigue.
Therefore, the possible benefits of early use of HFNC on the
outcomes of these patients remain uncertain.
Conclusion
In summary, the importance of this clinical case is to bring
to the clinician’s attention the potential value of this new
technique for oxygen administration, which made feasible
the practice of a diagnostic and therapeutic procedure that
otherwise might not have been tolerated or might have
required prior ETI and mechanical ventilation. HFNC could
be especially beneficial for obtaining lower respiratory
tract samples in patients who are difficult to diagnose,
thereby avoiding the risks of ETI. Lastly, in light of the
highly favorable tolerance to FBS with the use of HFNC,
early application of this examination can be considered in
patients with respiratory failure, and this would avert the
need for ETI, as was ultimately required in the patient
reported.
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